Latest On AstraZeneca PLC (AZNCF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-02-22 05:13 EST | Dividend | A dividend of $1.56 has been announced on Feb 8, 2024. It will be paid Mar 25, 2024 with an ex-dividend date of Feb 22, 2024. | Neutral |  |
| 2023-08-10 05:56 EST | Dividend | A dividend of $0.72 has been announced on Feb 9, 2023. It will be paid Sep 11, 2023 with an ex-dividend date of Aug 10, 2023. | Neutral | |
| 2023-02-23 04:56 EST | Dividend | A dividend of $1.63 has been announced on Feb 9, 2023. It will be paid Mar 27, 2023 with an ex-dividend date of Feb 23, 2023. | Neutral | |
| 2023-01-06 18:43 EST | News | AstraZeneca PLC 2022 Q3 - Results - Earnings Call Presentation | N/A | |
| 2022-12-21 13:25 EST | News | AstraZeneca: Most Promising Pharmaceutical Company During A Recession | N/A | |
| 2022-12-16 12:46 EST | News | AstraZeneca: Acquisitions And Some Thoughts About Biotech Investing | N/A | |
| 2022-09-13 20:29 EST | News | AstraZeneca PLC 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-08-25 21:00 EST | News | AstraZeneca: Lifeline Amid Double-Digit Inflation | N/A | |
| 2022-08-11 05:58 EST | Dividend | A dividend of $0.76 has been announced on Feb 10, 2022. It will be paid Sep 12, 2022 with an ex-dividend date of Aug 11, 2022. | Neutral | |
| 2022-06-24 16:58 EST | News | AstraZeneca: Our Next Growth Pick | N/A | |
| 2022-05-28 20:03 EST | News | AstraZeneca (AZN) Investor Presentations - Slideshow | N/A | |
| 2022-03-25 05:21 EST | News | AstraZeneca PLC 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-03-23 19:19 EST | News | AstraZeneca Is Looking As Polished As A New Aston Martin | N/A | |
| 2022-03-23 19:19 EST | News | AstraZeneca PLC (AZN) CEO Pascal Soriot on Q4 2021 Results - Earning Call Transcript | N/A | |
| 2022-02-24 04:56 EST | Dividend | A dividend of $1.45 has been announced on Feb 10, 2022. It will be paid Mar 28, 2022 with an ex-dividend date of Feb 24, 2022. | Neutral | |
| 2022-01-13 07:17 EST | News | AstraZeneca plc (AZN) Presents At The Virtual Lever Meeting 2021 - Slideshow | N/A | |
| 2021-12-23 03:25 EST | News | AstraZeneca PLC 2021 Q3 - Results - Earnings Call Presentation | N/A | |
| 2021-12-22 07:35 EST | News | AstraZeneca PLC (AZN) CEO Pascal Soriot on Q3 2022 Results - Earning Calls Transcript | N/A | |
| 2021-11-12 12:03 EST | News | AstraZeneca < | N/A | |
| 2021-10-30 03:21 EST | News | AstraZeneca PLC (AZN) Presents at ESMO Investor Science Broker Conference - (Transcript) | N/A | |
| 2021-09-08 19:14 EST | News | AstraZeneca PLC (AZN) CEO Pascal Soriot on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-09-07 23:38 EST | News | AstraZeneca PLC 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-08-12 06:00 EST | Dividend | A dividend of $0.65 has been announced on Feb 11, 2021. It will be paid Sep 13, 2021 with an ex-dividend date of Aug 12, 2021. | Neutral | |
| 2021-04-16 04:36 EST | News | AstraZeneca: No Longer Overpriced | N/A | |
| 2021-03-14 05:42 EST | News | AstraZeneca PLC's (AZN) CEO Pascal Soriot on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-12 15:01 EST | News | AstraZeneca PLC 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-02-25 05:00 EST | Dividend | A dividend of $1.37 has been announced on Nov 5, 2020. It will be paid Mar 29, 2021 with an ex-dividend date of Feb 25, 2021. | Neutral | |
| 2021-02-13 08:47 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-04 04:35 EST | News | AstraZeneca: The COVID-19 Vaccine Won't Create Much Value For Shareholders | N/A | |
| 2021-01-04 17:11 EST | News | AstraZeneca PLC (AZN) AstraZeneca to acquire Alexion Conference Call (Transcript) | N/A | |
| 2020-12-14 10:29 EST | News | AstraZeneca: Not Just A COVID-19 Play, But It's Pricey | N/A | |
| 2020-12-12 08:06 EST | News | AstraZeneca (AZN) Investor Presentation - Slideshow | N/A | |
| 2020-12-09 09:23 EST | News | AstraZeneca's (AZN) CEO Pascal Soriot on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-26 22:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 01:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 05:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-20 08:23 EST | News | AstraZeneca (AZN) Presents At Morgan Stanley 18th Annual Global Healthcare Conference - Slideshow | N/A | |
| 2020-09-26 14:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-23 22:13 EST | News | Who Is Ahead In The COVID-19 Vaccine Race? | N/A | |
| 2020-09-17 06:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-16 05:01 EST | News | COVID-19 Treatments: Remdesivir Disappoints, Antiviral SPL7013 And Monoclonal Antibodies Interesting For Prevention/Early-Stage Treatment | N/A | |
| 2020-08-28 10:57 EST | News | AstraZeneca PLC (AZN) CEO Pascal Soriot on Q2 2020 Results - Earnings Call Transcript | N/A | |
| 2020-08-26 00:07 EST | News | AstraZeneca PLC 2020 Q2 - Results - Earnings Call Presentation | N/A | |
| 2020-08-14 10:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-13 05:58 EST | Dividend | A dividend of $0.7 has been announced on Oct 24, 2019. It will be paid Sep 14, 2020 with an ex-dividend date of Aug 13, 2020. | Neutral | |
| 2020-08-06 10:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-01 06:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 18:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 06:24 EST | Financials | Company financials have been released. | Neutral | |
About AstraZeneca PLC (AZNCF):
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; and AliveCor, Inc. to develop non-invasive potassium monitoring solutions. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
General
- Name AstraZeneca PLC
- Symbol AZNCF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-General
- Full Time Employees 76,100
- Fiscal Year EndDecember
- Web URLhttp://www.astrazeneca.com
View More
Valuation
- Trailing PE 41.24
- Forward PE 20.12
- Price/Sales (Trailing 12 Mt.) 4.97
- Price/Book (Most Recent Quarter) 8.46
- Enterprise Value Revenue 5.36
- Enterprise Value EBITDA 17.11
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 12%
- Operating Margin 16%
- Return on Assets 4%
- Return on Equity 21%
- Revenue 26.62 billion
- Earnings Per Share $2.44
- Revenue Per Share $20.29
- Gross Profit 21.37 billion
- Quarterly Earnings Growth 11.2%
View More
ESG Rating
Highlights
- Market Capitalization 129.99 billion
- EBITDA 6.76 billion
- PE Ratio 37.13
- PEG Ratio 1.27
- Book Value Per Share $11.90
View More
Share Statistics
- Shares Outstanding 1.31 billion
- Shares Float 1.31 billion
- % Held by Insiders 32%
- % Held by Institutions 52.95%
View More
Technicals
- Beta 0.16
- 52 Week High $123.23
- 52 Week Low $74.36
- 50 Day Moving Average 99.8
- 200 Day Moving Average 104.89
View More
Dividends
- Forward Annual Dividend Rate $2.8
- Forward Annual Dividend Yield 2.79%
- Payout Ratio 109%
- Dividend Date 2019-09-09
- ExDividend Date 2021-02-25
- Dividend Per Share $2.8
- Dividend Yield 0%
View More
AstraZeneca PLC (AZNCF) Dividend Calendar:
AZNCF's last dividend payment was made to shareholders on September 9, 2019.
AstraZeneca PLC pays out 109% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
AstraZeneca PLC (AZNCF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $7.41 billion | $0.77 | ||
| 2020-09-30 | 2020-12-31 | $6.58 billion | $0.77 | ||
| 2020-06-30 | 2020-09-30 | $6.28 billion | $0.49 | $0.90 | -45.56% |
| 2020-03-31 | 2020-06-30 | $6.35 billion | $0.58 | $0.90 | -35.98% |
| 2019-12-31 | 2020-03-31 | $6.66 billion | $0.59 | $1.01 | -41.58% |
| 2019-09-30 | 2019-12-31 | $6.41 billion | $0.24 | $0.96 | -75.15% |
| 2019-06-30 | 2019-09-30 | $5.82 billion | $0.23 | $0.63 | -63.83% |
| 2019-03-31 | 2019-06-30 | $5.49 billion | $0.10 | $0.86 | -88.47% |
| 2018-12-31 | 2019-03-31 | $6.42 billion | $0.47 | $1.47 | -68.16% |
| 2018-09-30 | 2018-12-31 | $5.34 billion | $0.82 | $0.69 | 18.28% |
| 2018-06-30 | 2018-09-30 | $3.78 billion | $0.34 | $0.68 | -50% |
| 2018-03-31 | 2018-06-30 | $5.18 billion | $0.27 | $0.60 | -55% |
| 2017-12-31 | 2018-03-31 | $5.78 billion | $0.27 | $0.85 | -68.4% |
| 2017-09-30 | 2017-12-31 | $4.88 billion | $1.03 | $1.09 | -5.72% |
| 2017-06-30 | 2017-09-30 | $5.05 billion | $0.54 | $0.79 | -31.65% |
| 2017-03-31 | 2017-06-30 | $5.41 billion | $0.38 | $0.81 | -53.48% |
| 2016-12-31 | 2017-03-31 | $0.42 | $1.15 | -63.48% | |
| 2016-09-30 | 2016-12-31 | $1.45 | $0.99 | 46.46% | |
| 2016-06-30 | 2016-09-30 | $0.80 | $0.83 | -3.61% | |
| 2016-03-31 | 2016-06-30 | $-0.00 | $0.93 | -100.26% | |
| 2015-12-31 | 2016-03-31 | $0.51 | $0.95 | -46.32% | |
| 2015-09-30 | 2015-12-31 | $0.64 | $1.03 | -37.94% | |
| 2015-06-30 | 2015-09-30 | $0.60 | $1.04 | -42.31% | |
| 2015-03-31 | 2015-06-30 | $0.55 | $1.06 | -48.11% | |
| 2014-12-31 | 2015-03-31 | $0.44 | $0.82 | -46.89% | |
| 2014-09-30 | 2014-12-31 | -$0.25 | $1.01 | -125.17% | |
| 2014-06-30 | 2014-09-30 | $0.20 | |||
| 2014-03-31 | 2014-06-30 | $0.63 | |||
| 2013-12-31 | 2014-03-31 | $0.40 | |||
| 2013-09-30 | 2013-12-31 | -$0.42 | |||
| 2013-06-30 | 2013-09-30 | $0.99 | |||
| 2013-03-31 | 2013-06-30 | $0.66 | |||
| 2012-12-31 | 2013-03-31 | $0.81 | |||
| 2012-09-30 | 2012-12-31 | $1.21 | |||
| 2012-06-30 | 2012-09-30 | $1.20 | |||
| 2012-03-31 | 2012-06-30 | $1.26 | |||
| 2011-12-31 | 2012-03-31 | $1.27 | |||
| 2011-09-30 | 2011-12-31 | $1.13 | |||
| 2011-06-30 | 2011-09-30 | $2.54 | |||
| 2011-03-31 | 2011-06-30 | $1.53 | |||
| 2010-12-31 | 2011-03-31 | $2.07 | |||
| 2010-09-30 | 2010-12-31 | $1.14 | |||
| 2010-06-30 | 2010-06-30 | $1.45 | |||
| 2010-03-31 | 2010-03-31 | $1.90 | |||
| 2009-12-31 | 2009-12-31 | $1.07 | |||
| 2009-09-30 | 2009-09-30 | $1.46 | |||
| 2009-06-30 | 2009-06-30 | $1.18 | |||
| 2009-03-31 | 2009-03-31 | $1.48 | |||
| 2008-12-31 | 2008-12-31 | $0.86 | |||
| 2008-09-30 | 2008-09-30 | $1.19 | |||
| 2008-06-30 | 2008-06-30 | $1.11 | |||
| 2008-03-31 | 2008-03-31 | $1.03 | |||
| 2007-12-31 | 2007-12-31 | $0.86 | |||
| 2007-09-30 | 2007-09-30 | $0.90 | |||
| 2007-06-30 | 2007-06-30 | $0.95 | |||
| 2007-03-31 | 2007-03-31 | $1.02 | |||
| 2006-12-31 | 2006-12-31 | $0.93 | |||
| 2006-09-30 | 2006-09-30 | $1.01 | |||
| 2006-06-30 | 2006-06-30 | $1.01 | |||
| 2006-03-31 | 2006-03-31 | $0.90 | |||
| 2005-12-31 | 2005-12-31 | $0.77 | |||
| 2005-09-30 | 2005-09-30 | $0.76 | |||
| 2005-06-30 | 2005-06-30 | $0.75 | |||
| 2005-03-31 | 2005-03-31 | $0.63 | |||
| 2004-12-31 | 2004-12-31 | $0.58 | |||
| 2004-09-30 | 2004-09-30 | $0.72 | |||
| 2004-06-30 | 2004-06-30 | $0.50 | |||
| 2004-03-31 | 2004-03-31 | $0.47 | |||
| 2003-12-31 | 2003-12-31 | $0.37 | |||
| 2003-09-30 | 2003-09-30 | $0.47 |
AstraZeneca PLC (AZNCF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 1.72 billion | 1.45 billion | 1.39 billion | 1.39 billion | 2.07 billion |
| Income Before Tax | 1.17 billion | 853 million | 961 million | 935 million | 240 million |
| Selling General Administrative | 3.32 billion | 2.27 billion | 2.74 billion | 2.81 billion | 3.09 billion |
| Gross Profit | 5.89 billion | 5.21 billion | 5.29 billion | 4.93 billion | 5.24 billion |
| Ebit | 2.29 billion | 1.98 billion | 2 billion | 2.11 billion | 573 million |
| Operating Income | 1.49 billion | 1.32 billion | 1.28 billion | 1.22 billion | 573 million |
| Income Tax Expense | 162 million | N/A | 223 million | 185 million | -37 million |
| Total Revenue | 7.41 billion | 6.58 billion | 6.28 billion | 6.35 billion | 6.66 billion |
| Cost of Revenue | 1.53 billion | 1.37 billion | 984 million | 1.42 billion | 1.43 billion |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -333 million |
| Net Income From Continuing Operations | 1.01 billion | 651 million | 738 million | 750 million | 277 million |
| Net Income Applicable to Common Shares | 1.01 billion | N/A | 756 million | 780 million | 313 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | -580 million | 148 million | 9 million | -34 million | 166 million |
| Change to Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | N/A | 148 million | 9 million | 58 million | 74 million |
| Net Borrowings | N/A | 1.12 billion | 123 million | -16 million | -1.54 billion |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | 6 million | -2.71 billion |
| Change to Operating Activities | N/A | -335 million | -445 million | 466 million | -178 million |
| Change in Cash | 2.49 billion | 2.31 billion | -2.21 billion | 1.44 billion | -1.55 billion |
| Total Cash from Operating Activities | 1.82 billion | 1.04 billion | 139 million | 1.38 billion | 1.1 billion |
| Depreciation | 801 million | 710 million | 841 million | 1.11 billion | 716 million |
| Other Cash Flow from Investing Activities | N/A | 9 million | 28 million | 17 million | 35 million |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | -93 million | N/A | -22 million |
| Change to Net Income | N/A | -89 million | -1.04 billion | -514 million | 266 million |
| Capital Expenditures | 705 million | 977 million | 376 million | 320 million | 221 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 51.09 billion | 50.49 billion | 46.27 billion | 45 billion | 46.78 billion |
| Total Stockholder Equity | 15.62 billion | 12.2 billion | 12.24 billion | 10.78 billion | 13.13 billion |
| Other Current Liabilities | 2.1 billion | N/A | N/A | N/A | 2.08 billion |
| Total Assets | 66.73 billion | 64.11 billion | 59.93 billion | 57.21 billion | 61.38 billion |
| Common Stock | 328 million | N/A | 328 million | 328 million | 328 million |
| Other Current Assets | 142 million | N/A | N/A | N/A | 106 million |
| Retained Earnings | 5.3 billion | 1.88 billion | 1.91 billion | 448 million | 2.81 billion |
| Other Liabilities | 10.49 billion | N/A | 10.13 billion | 9.48 billion | 10.28 billion |
| Other Assets | 4.33 billion | N/A | 3.9 billion | 3.59 billion | 3.52 billion |
| Cash | 7.83 billion | 8.07 billion | 5.67 billion | 3.41 billion | 5.37 billion |
| Total Current Liabilities | 20.31 billion | 18.94 billion | 18.18 billion | 17.04 billion | 18.12 billion |
| Other Stockholder Equity | 2.02 billion | N/A | 2.05 billion | 2.06 billion | 2.05 billion |
| Property, Plant & Equipment | 8.92 billion | N/A | 8.11 billion | 7.99 billion | 8.34 billion |
| Total Current Assets | 19.54 billion | 18.17 billion | 14.93 billion | 12.82 billion | 15.56 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 1.46 billion |
| Net Tangible Assets | -17.17 billion | N/A | -19.14 billion | -20.51 billion | -19.37 billion |
| Short Term Investments | 160 million | 374 million | 442 million | 752 million | 849 million |
| Long Term Debt | 17.51 billion | 18.27 billion | 15.15 billion | 15.63 billion | 17.89 billion |
| Inventory | 4.02 billion | 3.68 billion | 3.56 billion | 3.12 billion | 3.19 billion |
| Accounts Payable | 15.79 billion | 13.41 billion | 12.03 billion | 12.63 billion | 13.99 billion |
AstraZeneca PLC (AZNCF) Chart:
AstraZeneca PLC (AZNCF) News:
Below you will find a list of latest news for AstraZeneca PLC (AZNCF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
AstraZeneca PLC (AZNCF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
AstraZeneca PLC (AZNCF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|